Cite
HARVARD Citation
Jahanzeb, M. et al. (n.d.). 1398PReal-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC). Annals of oncology. p. . [Online].